Hemophilia is a bleeding disorder that affects about 13,000 people in the United States. Two types of hemophilia have been identified, hemophilia A and hemophilia B, which result from the deficiency of clotting factor VIII and IX, required for blood coagulation. Current treatment of the hemophilic patients requires frequent factor VIII or factor IX replacements to prevent bleeding. Unfortunately, many patients are exposed to blood-borne diseases like hepatitis and AIDS. Gene therapy offers an opportunity to cure the disease by introducing genes capable of synthesizing sustained and therapeutic amounts of clotting factors. Towards this goal we have proposed the use of novel gene transfer approaches to introduce factor IX and factor VIII genes in vivo by adeno-associated viral (AAV) vectors and novel lentiviral vectors. The availability of factor IX and factor VIII deficient mice offers an excellent experimental model system. Initial results indicate that AAV vectors containing factor IX gene transcribed from a liver specific promoter upon injection into the portal vein of mice deficient in factor IX (factor IX """"""""knockout"""""""") produce well above therapeutic levels of factor IX for over eight weeks. Similarly, intraportal injection of lentiviral vectors generating factor VIII into factor VIII """"""""knockout"""""""" mice show production of therapeutic levels of factor VIII protein in plasma. We plan to introduce factor IX and factor VIII producing recombinant viruses in hemophilic dogs deficient in factor IX or factor VIII protein. We also propose to transduce hematopoietic stem cells for producing factor IX or VIII protein. Additionally, we will generate cell lines capable of producing high quality and safe recombinant vectors. We believe the proposed experiments will give us sufficient information to consider clinical protocols, the long term goal of this proposal. Finally, we believe that the knowledge gained from gene therapy of hemophilia will serve as an excellent model system for many genetic diseases.
| Friedmann-Morvinski, D; Bhargava, V; Gupta, S et al. (2016) Identification of therapeutic targets for glioblastoma by network analysis. Oncogene 35:608-20 |
| Sancho-Martinez, Ignacio; Nivet, Emmanuel; Xia, Yun et al. (2016) Establishment of human iPSC-based models for the study and targeting of glioma initiating cells. Nat Commun 7:10743 |
| Friedmann-Morvinski, Dinorah; Narasimamurthy, Rajesh; Xia, Yifeng et al. (2016) Targeting NF-?B in glioblastoma: A therapeutic approach. Sci Adv 2:e1501292 |
| Wickersham, Ian R; Sullivan, Heather A; Pao, Gerald M et al. (2015) Lentiviral vectors for retrograde delivery of recombinases and transactivators. Cold Spring Harb Protoc 2015:368-74 |
| Menon, Tushar; Firth, Amy L; Scripture-Adams, Deirdre D et al. (2015) Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs. Cell Stem Cell 16:367-72 |
| Font-Burgada, Joan; Shalapour, Shabnam; Ramaswamy, Suvasini et al. (2015) Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer. Cell 162:766-79 |
| Firth, Amy L; Menon, Tushar; Parker, Gregory S et al. (2015) Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated from Patient iPSCs. Cell Rep 12:1385-90 |
| Friedmann-Morvinski, Dinorah; Verma, Inder M (2014) Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep 15:244-53 |
| Agemy, Lilach; Kotamraju, Venkata R; Friedmann-Morvinski, Dinorah et al. (2013) Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32. Mol Ther 21:2195-204 |
| Soda, Yasushi; Myskiw, Chad; Rommel, Amy et al. (2013) Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) 91:439-48 |
Showing the most recent 10 out of 23 publications
